RxDoctor Payments Data

Uy Nguyen, MD

Internal Medicine · Arlington, VANPI 1194831065

Payments from drug & device makers

$12,028in general payments, 2019–2025

Across 605 payments — averaging $19.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$1K
  • Gilead$1K
  • Novo Nordisk$910
  • Amgen$840
  • AstraZeneca$713
  • plus $5K from 51 others

What the payments were for

  • Food & beverage$12,008100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,028 in reported general payments places this provider in the 95th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$166,068
Medicare patients
273
Services billed
1,882

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban142$180,027
ProliaDenosumab40$70,660
Lidocaine572$69,316
JardianceEmpagliflozin45$65,156
JanuviaSitagliptin Phosphate52$64,479
OzempicSemaglutide46$63,419
TrulicityDulaglutide42$58,255
VascepaIcosapent Ethyl111$55,535
FarxigaDapagliflozin Propanediol47$52,401
LinzessLinaclotide34$33,128
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate30$29,758
MyrbetriqMirabegron36$26,793
EntrestoSacubitril/Valsartan17$24,826
RestasisCyclosporine34$24,800
AbrysvoRsv Vacc, Pref A And Pref B/Pf82$24,751

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$1,260$204,778224 claims
Boehringer IngelheimJardiance, Tradjenta$204$85,09558 claims
Novo NordiskOzempic, Rybelsus$910$80,01960 claims
AmgenProlia$840$70,66040 claims
AstraZenecaFarxiga, Brilinta$713$67,13258 claims
MerckJanuvia$124$64,47952 claims
Lilly USA, LLCTrulicity$583$58,25542 claims
AbbVieLinzess, Restasis$1,715$57,92968 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$541$48,323124 claims
Astellas Pharma US IncMyrbetriq$139$26,79336 claims
NovartisEntresto$147$24,82617 claims
Scilex Pharmaceuticals Inc.Colchicine$99$10,17843 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Arlington

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →